Ollin Biosciences
Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD
$330MSeries B
Role not disclosedTR
T. Rowe Price Investment Management
Activity from announced rounds
Activity in this selectionSeries B
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $580M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionMirador Therapeutics
Develops next-generation therapies for immune-mediated inflammatory and fibrotic diseases
$250MSeries B
Role not disclosed